Analysts Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) PT at $33.84

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have been given a consensus rating of “Hold” by the twenty-eight analysts that are presently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and nine have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $33.84.

A number of brokerages recently weighed in on SRPT. Piper Sandler lifted their price target on Sarepta Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a research note on Thursday, October 30th. Guggenheim decreased their price objective on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Barclays started coverage on Sarepta Therapeutics in a report on Wednesday, January 28th. They issued an “equal weight” rating and a $20.00 target price on the stock. Bank of America boosted their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company an “underperform” rating in a report on Wednesday, October 22nd. Finally, Wedbush increased their price objective on Sarepta Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $18.31 on Thursday. The firm’s fifty day simple moving average is $21.43 and its 200 day simple moving average is $20.09. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of -6.08, a PEG ratio of 0.46 and a beta of 0.39. Sarepta Therapeutics has a twelve month low of $10.41 and a twelve month high of $114.41. The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78.

Insider Buying and Selling at Sarepta Therapeutics

In related news, COO Ian Michael Estepan sold 13,187 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the transaction, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at approximately $4,312,523. This trade represents a 6.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 7.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. CWM LLC raised its stake in Sarepta Therapeutics by 4,033.3% during the 3rd quarter. CWM LLC now owns 72,705 shares of the biotechnology company’s stock worth $1,401,000 after buying an additional 70,946 shares during the period. Aberdeen Group plc increased its stake in shares of Sarepta Therapeutics by 91.1% during the 2nd quarter. Aberdeen Group plc now owns 1,242,404 shares of the biotechnology company’s stock worth $21,500,000 after purchasing an additional 592,125 shares during the last quarter. 683 Capital Management LLC raised its stake in Sarepta Therapeutics by 309.1% in the 2nd quarter. 683 Capital Management LLC now owns 675,000 shares of the biotechnology company’s stock valued at $11,542,000 after acquiring an additional 510,000 shares during the period. State of New Jersey Common Pension Fund D boosted its holdings in shares of Sarepta Therapeutics by 59.9% in the second quarter. State of New Jersey Common Pension Fund D now owns 48,555 shares of the biotechnology company’s stock worth $830,000 after acquiring an additional 18,190 shares during the period. Finally, Edgestream Partners L.P. grew its stake in Sarepta Therapeutics by 870.3% during the second quarter. Edgestream Partners L.P. now owns 82,979 shares of the biotechnology company’s stock valued at $1,419,000 after acquiring an additional 74,427 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.